Mass. Bio members distraught over new controversy

With a fresh controversy swirling around newly appointed Executive Director Robert Coughlin, the Massachusetts Biotechnology Council is being hit with criticism from its own members concerned that the group is constantly finding itself mired in one political scrap after the next. Coughlin has been hit with allegations that he had a conflict when he worked as an aide to the governor, developing biotech initiatives while he was being considered for the top post on the council. His predecessor, former House Speaker Thomas Finneran, was forced to resign after he pleaded guilty to obstruction charges.

"It's a real shame," Alison Taunton-Rigby, chief executive of RiboNovix, told The Boston Globe. "We are an industry that is very clean and very pure and it hurts to have things like this happen."

- here's the article from The Boston Globe

Suggested Articles

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development. 

In a pandemic world, the biotech funding environment couldn’t look brighter, and today Pfizer shone its own light.

Gilead is tapping long-term Stanford University researcher Mark Genovese, M.D., to lead its NASH, fibrosis and arthritis pipeline programs.